PRTK - Paratek Pharmaceuticals, Inc.
Paratek Pharmaceuticals, Inc.
75 Park Plaza
3rd Floor
Boston, MA 02116
United States
617 807 6600
https://www.paratekpharma.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 268
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Michael F. Bigham CPA, CPA, M.B.A., MBA | Exec. Chairman | 954.39k | N/A | 1958 |
| Dr. Evan Loh FACC, FAHA, M.D. | CEO & Director | 1.14M | N/A | 1959 |
| Mr. Adam Woodrow | Pres & Chief Commercial Officer | 763.51k | N/A | 1967 |
| Ms. Sarah Higgins | VP of Fin., Controller & Principal Accounting Officer | N/A | N/A | 1975 |
| Mr. William M. Haskel | Sr. VP, Chief Legal Officer, Gen. Counsel & Corp. Sec. | N/A | N/A | 1962 |
| Mr. Jonathan Light | Deputy Gen. Counsel & Chief Compliance Officer | N/A | N/A | N/A |
| Ms. Karen McGrath | Chief People Officer | N/A | N/A | N/A |
| Mr. Randall B. Brenner | Chief Devel. & Regulatory Officer | N/A | N/A | 1973 |
Description
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its products include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia, and acute skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a once-daily oral therapy for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. It also has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. The company was founded in 1996 and is headquartered in Boston, Massachusetts.
Corporate Governance
Paratek Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
